More evidence evolocumab exceeds cost-effectiveness
(HealthDay)—At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published ...
Aug 25, 2017
0
0